Cue Biopharma盘前股价飙升48.2%,Cue-221荨麻疹治疗中期研究传来捷报

美股速递
Sep 21

Cue Biopharma股价在盘前交易中暴涨48.2%。这一惊人涨幅源于该公司针对其候选药物Cue-221在荨麻疹治疗领域所开展的中期研究取得了积极成果。市场对此反应热烈,投资者情绪高涨。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10